Health Care

Alex B. Boyle & Cass R. Sunstein, Positive and negative framing of complication risk and long-term outcomes influences decision-making in hip and knee arthroplasty, 23…

Daniel G. Aaron, I. Glenn Cohen & Eli Y. Adashi, Medicare Advantage Under Fire: Public Criticism and Implications, J. Gen. Internal Med. (2024).

Betina Idnay, Zihan Xu, William G. Adams et al., Environment scan of generative AI infrastructure for clinical and translational science, 2 npj Health Sys. (2025).

Eli Y. Adashi, Daniel P. O’Mahony & I. Glenn Cohen, Declining U.S. Fertility and Births Rates: A Shrinking Nation, J. Women’s Health (2024).

Eli Y. Adashi & I. Glenn Cohen, Hippocratic Beneficence: The Ethical Grounding of Remedial Germline Editing, 25 Am. J. Bioethics 7 (2025).

Sara Gerke, Carmel Shachar, Peter R. Chai & I. Glenn Cohen, Regulatory, Safety, and Privacy Concerns of Home Monitoring Technologies During COVID-19, 26 Nature Med.

Carmel Shachar, Jaclyn Engel & Glyn Elwyn, Implications for Telehealth in a Postpandemic Future: Regulatory and Privacy Issues, 323 JAMA 2375 (2020).

Samuel G. Finlayson, Adarsh Subbaswamy, Karandeep Singh, John Bowers, Annabel Kupke, Jonathan Zittrain, Isaac S. Kohane & Suchi Saria, The Clinician and Dataset Shift in…

Eli Y. Adashi, Philip A. Gruppuso & I. Glenn Cohen, CRISPR Therapy of Sickle Cell Disease: The Dawning of the Gene Editing Era, Am. J.

Amy L. McGuire, I. Glenn Cohen, Dominic Sisti et al., Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement, 7 JAMA…

Mason Marks, I. Glenn Cohen, Jonathan Perez- Reyzin et al., Microdosing Psychedelics Under Local, State, and Federal Law, 103 B.U. L. Rev. 101 (2023).

Mason Marks & I. Glenn Cohen, How Should the FDA Evaluate Psychedelic Medicine?, 389 New England J. Med. 1733 (2023).

Timo Minssen, Effy Vayena & I. Glenn Cohen, The Challenges for Regulating Medical Use of ChatGPT and Other Large Language Models, 330 JAMA 315 (2023).

Eli Y. Adashi, Daniel P. O’Mahony & I. Glenn Cohen, The FDA Modernization Act 2.0: Drug Testing in Animals is Rendered Optional, Am. J. Med.

Kushal T. Kadakia, Celynne A. Balatbat, Albert L. Siu et al., Hospital‐at‐Home: Multistakeholder Considerations for Program Dissemination and Scale, 100 Milbank Q. 673 (2022).

David A. Simon, Carmel Shachar & I. Glenn Cohen, Skating the line between general wellness products and regulated devices: Strategies and implications, 9 J. L.

Carmel Shachar, Tess Wise, Gali Katznelson, et al., Criminal Justice or Public Health: A Comparison of the Representation of the Crack Cocaine and Opioid Epidemics…

Katrine Bach Habersaat, Cornelia Betsch, Margie Danchin, Cass R. Sunstein, Robert Böhm, Armin Falk, Noel T. Brewer, Saad B. Omer, Martha Scherzer, Sunita Sah et…

David A. Simon, Sara Raza, Carmel Shachar et al., Using Digital Technologies to Diagnose in the Home: Recommendations from a Delphi Panel, npj Digital Med.

Mason Marks & I. Glenn Cohen, Psychedelic Therapy: A Roadmap for Wider Acceptance and Utilization, 27 Nat. Med. 1669 (2021).

John H. Rex, Holly Fernandez Lynch, I. Glenn Cohen, Jonathan J. Darrow & Kevin Outterson, Designing Development Programs for Non-Traditional Antibacterial Agents, 10 Nature Comm.